Evidence map›Paper›PMID 41915241›Full record

ArticleNeurosurgical review2026

Combined surgery and proton radiotherapy in the management of craniopharyngiomas: an update with paradigmatic and challenging case scenarios.

Federico Valeri, Matteo Zoli, Sara Lillo, Francesco Tengattini, Francesca Colombo, Ernesto Pasquini, Gennaro Salierno, Alessandro Carretta, Luca D'Ambrosio, Daniel Babaei and 7 more

Abstract readCase Reports
In one paragraph

Article in Neurosurgical review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Federico Valeri *Department of Neurosurgery, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Matteo Zoli *Programma Neurochirurgia Ipofisi - Pituitary Unit, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Sara Lillo *Radiation Oncology Unit, Clinical Department, C.N.A.O (National Center for Oncological Hadrontherapy), Pavia, Italy.
Francesco TengattiniNeurosurgery, Department of Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy. f.tengattini003@unibs.it.
Francesca ColomboRadiation Oncology Unit, Clinical Department, C.N.A.O (National Center for Oncological Hadrontherapy), Pavia, Italy.
Ernesto PasquiniENT Department, Bellaria Hospital AUSL di Bologna, Bologna, Italy.
Gennaro SaliernoNeurosurgery, Department of Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
Alessandro CarrettaDepartment of Biomedical and Neuromotor Sciences (DIBINEM), University of Bologna, Bologna, Italy.
Luca D'AmbrosioRadiation Oncology Unit, Clinical Department, C.N.A.O (National Center for Oncological Hadrontherapy), Pavia, Italy.
Daniel BabaeiRadiation Oncology Unit, Clinical Department, C.N.A.O (National Center for Oncological Hadrontherapy), Pavia, Italy.
Edoardo AgostiNeurosurgery, Department of Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
Pier Paolo MattognoDepartment of Neurosurgery, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Marco Maria FontanellaNeurosurgery, Department of Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
Liverana LaurettiFaculty of Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy.
Diego Mazzatenta *Programma Neurochirurgia Ipofisi - Pituitary Unit, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Francesco Doglietto *Department of Neurosurgery, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Alberto Iannalfi *Radiation Oncology Unit, Clinical Department, C.N.A.O (National Center for Oncological Hadrontherapy), Pavia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCraniopharyngiomas are rare, benign tumors whose relationship with crucial neurovascular structures poses a significant surgical challenge. The endoscopic endonasal approach has improved outcomes, but in cases of optic pathways or hypothalamic involvement, complete resection is impossible without significant functional deficits. Subtotal resection followed by radiation therapy has been achieving comparable rates of tumor control to gross total resection alone. Proton therapy (PRT) achieves comparable oncological outcomes to photon therapy, but with better functional outcomes thanks to its capability of sparing surrounding healthy tissues. Herein we summarize the most recent evidence on the use of PRT for craniopharyngiomas and provides paradigmatic, challenging case scenarios managed with a combination of surgery and PRT.

methodsEight patients who were treated with PRT for craniopharyngiomas between January 2016 and September 2023 are presented. Patients underwent thorough endocrinological, clinical, cognitive, and radiological evaluation before and after treatment.

resultsAll patients underwent at least one surgical procedure. One patient was treated with primary PRT. Five patients presented with visual impairment before treatment. All 8 cases had some degree of endocrinological dysfunction before PRT. Four patients presented signs of hypothalamic dysfunction. Seven patients received a conventional cycle of treatment (54 GyRBE total, 1.8 GyRBE/fraction, 30 fractions), but one patient received 52.5 GyRBE in 29 fractions with caution due to pre-treatment bitemporal hemianopia and old age. One patient’s visual acuity worsened within grade 2 (according to CTCAE v5.0), while all the others improved or remained stable after treatment. Endocrinological status improved in one case and remained stable in the others. Hypothalamic dysfunction worsened in two patients and improved in two. In one case, a complete response was achieved, in one the tumor remained stable, and the remaining six achieved a partial response with reduction ≥ 50%. A case with brain multifocal dissemination was successfully treated with surgery and systemic therapy, and concomitant asymptomatic early radio-induced contrast enhancement was observed. Median follow-up spanned 58.5 months (range: 24–72).

conclusionsPRT appears as a safe and feasible option for the management of craniopharyngiomas, especially for children and in cases of adherence to the optic pathways or hypothalamus, and generally in various challenging case scenarios. From a modern neuro-oncological perspective, multimodal function-sparing management should be favored over aggressive surgery.

Indexed as

CraniopharyngiomaNeurosurgical ProceduresPituitary NeoplasmsProton TherapyChildChild, PreschoolCombined Modality TherapyFemaleHumansInfantMaleTreatment OutcomeCraniopharyngiomaEndoscopic endonasalFractionated radiotherapyHypothalamic syndromeProton radiotherapy

Identifiers

PMID41915241
PMCPMC13038692

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.